

Diabetes mellitus among pulmonary tuberculosis patients from four TB-endemic countries: the TANDEM study

Cesar Ugarte-Gil^{1,2,3}

Bachti Alisjahbana^{4,5}

Katharina Ronacher^{6,7}

Anca Lelia Riza^{8,9,10}

Raspati C. Koesoemadinata^{5,11}

Stephanus T. Malherbe⁶

Ramona Cioboata¹²

Juan Carlos Llontop¹³

Leanie Kleynhans⁶

Sonia Lopez¹⁴

Prayudi Santoso^{4,5}

Ciontea Marius¹⁵

Katerine Villaizan¹⁴

Rovina Ruslami^{5,11}

Gerhard Walzl⁶

Nicolae Mircea Panduru¹⁶

Hazel M. Dockrell¹⁷

Philip C. Hill¹⁸

Susan Mc Allister¹⁸

Fiona Pearson¹⁹

David A.J. Moore^{3,14}

Julia A. Critchley¹⁹

Reinout van Crevel⁸

On behalf of TANDEM Consortium

1. School of Medicine, Universidad Peruana Cayetano Heredia, Lima, Perú
2. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
3. TB Centre, London School of Hygiene and Tropical Medicine, London, United Kingdom
4. Department of Internal Medicine, Hasan Sadikin Hospital, Bandung, Indonesia
5. Infectious Disease Research Center, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
6. DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
7. Translational Research Institute, Mater Research Institute – The University of Queensland, Brisbane, Australia
8. Department of Internal Medicine and Radboud Center of Infectious Diseases, Radboud university medical center, Nijmegen, the Netherlands
9. Human Genomics Laboratory, University of Medicine and Pharmacy of Craiova, Craiova, Romania
10. Regional Centre for Human Genetics – Dolj, Emergency Clinical County Hospital, Craiova, Romania
11. Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
12. Hospital for Infectious Diseases and Pneumology "Victor Babeş" Craiova, Romania
13. Hospital de Huaycan, Lima, Perú
14. Laboratorios de Investigación y Desarrollo, Universidad Peruana Cayetano Heredia, Lima, Perú
15. Pneumology Hospital Tudor Vladimirescu, Dobrita, jud. Gorj, Romania
16. 2nd Clinical Department, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
17. Department of Immunology & Infection, London School of Hygiene & Tropical Medicine, London, United Kingdom.

18. Centre for International Health, University of Otago Medical School, University of Otago, Dunedin, New Zealand
19. Population Health Research Institute, St Georges, University of London. United Kingdom

Correspondence:

Fiona Pearson PhD, Population Health Research Institute, St Georges, University of London. Cranmer Terrace. London. SW17 0RE (+44)-0206729944 fpearson@sgul.ac.uk

Summary:

Prevalence and characteristics of DM in TB patients vary considerably between countries, underlining the need for country and setting specific information. However, in all four countries, the majority of DM among TB patients was previously diagnosed but poorly controlled. Amongst individuals with TB-DM DM complications were highly prevalent as were comorbidities and CVD risk was raised.

Abstract:

Background. Diabetes mellitus (DM) increases the risk of active tuberculosis (TB) and worsens TB outcomes, putting TB control in jeopardy especially in TB endemic countries with rising DM prevalence rates. We assessed DM status and clinical correlates in TB patients across settings in Indonesia, Peru, Romania and South Africa.

Methods. Age-adjusted DM prevalence was estimated using laboratory glycated haemoglobin (HbA1c) or fasting plasma glucose (FPG) in TB patients. Detailed and standardized socio-demographic, anthropometric and clinical measurements were made. Characteristics of TB patients with or without DM were compared using multi-level mixed effect regression models with robust standard errors.

Results. Of 2185 TB patients (median 36.6 years, 61.2% male, 3.8% HIV-infected), 12.5% (267/2128) had DM, 1/3 of whom were newly diagnosed. Age-standardized DM prevalence ranged from 10.9% (South Africa) to 19.7% (Indonesia). Median HbA1c in TB-DM patients ranged from 7.4% (Romania) to 11.3% (Indonesia). Compared to those without DM, TB-DM patients were older with higher Body Mass Index (BMI) (p-value<0.05). Compared to those with newly diagnosed DM, TB patients previously known to have DM had higher BMI and HbA1c, less severe TB, and more frequent comorbidities, DM complications and hypertension (p-value<0.05).

Conclusions: We show that DM prevalence and clinical characteristics of TB-DM vary considerably between countries. Diabetes is mostly known but untreated, hyperglycemia is often severe, and many patients with combined TB and DM have significant cardiovascular disease risk and severe TB, underlining the need to improve strategies for better clinical management of combined TB and DM.

Keywords: Tuberculosis, Diabetes, syndemic, Prevalence, HbA1c

Introduction

Prevalence of type 2 Diabetes Mellitus (DM) has been increasing in low and middle-income countries (LMICs), in areas that also have high TB incidence [1, 2]. DM increases the risk of active TB 3-fold and worsens disease outcomes[3]. There were about 10 million cases of TB and 1.3 million deaths due to TB globally in 2017 [4]. Global TB incidence rates are currently modestly declining, and rising DM prevalence threatens global TB control [4]. Despite expanding evidence on the effect of DM on TB risk and outcome, and increasing insights upon mechanisms underlying these effects[5], there are limited global data on those with combined TB and DM. Neither the Global Tuberculosis Report (2018) [4] or related World Health Organization (WHO) documents report TB-DM numbers worldwide (in contrast to the national level data on TB-HIV), which makes assessment of the burden of this co-morbidity challenging. Much of the available TB-DM data is based on retrospective studies, which could underestimate the scale of TB-DM comorbidity, particularly as a high proportion of DM is believed to be undiagnosed in LMICs[6]. Furthermore, most studies have been conducted on cohorts of TB patients using routine or administrative data (e.g. TB program registries) in which key risk factor and clinical data associated with DM (such as hypertension, anthropometric measures, cardiovascular health, DM duration, medication or control) are not routinely recorded. This data gap constrains capacity to provide a complete characterization of patients with TB-DM and hinders the ability to design appropriate TB-DM screening and management strategies.

As part of an EU-funded consortium[7], TB patients from four epidemiologically distinct settings (Indonesia, Peru, Romania and South Africa) were investigated for co-morbid

DM, facilitating standardized, prospective comparison of populations with differences in DM and TB prevalence, ethnicity and health systems. We report the country specific, age-adjusted prevalence and clinical characteristics of TB patients presenting with previously diagnosed DM, newly diagnosed DM, and intermediate hyperglycaemia, along with an evaluation of possible risk factors, amongst newly diagnosed TB patients in each setting.

Material and methods

Study design and study population

This study was part of TANDEM[7], a consortium exploring the interaction between TB and DM. Details of the sites and definitions were described elsewhere[8].

Study measurements and definitions

We defined individuals with pulmonary TB if they initiated treatment at a local TB program, based on bacteriological (sputum smear, sputum culture or Xpert test), radiological and/or clinical evidence. Further details are published elsewhere[9, 10] and are freely available in online appendices[8].

All participants underwent laboratory HbA1c testing (using the High Performance Liquid Chromatography method), as recommended by WHO for DM screening,[11] regardless of their previous DM status. Random plasma glucose (RPG) was measured and if >110 mg/dL but <200 mg/dL (the recognised cut point for diagnosing DM if symptomatic) this was also followed with a fasting blood glucose (FPG) test. Patients were deemed to have DM if they had repeated tests (HbA1c, RPG or FPG) above the diagnostic threshold, see Appendix 1.

‘Previously diagnosed DM’ was defined as any patient who self-reported a doctor diagnosis of DM and was either taking standard anti-DM drugs at the time of recruitment or had a subsequent study HbA1c of $\geq 6.5\%$. ‘Newly diagnosed DM’ was defined ~~principally~~ based on repeated laboratory testing (see Appendix 1), mostly HbA1c. Intermediate hyperglycaemia (or ‘pre-diabetes’; raised blood glucose or HbA1c above normal, but below the threshold for identifying DM) was defined as patients with a single measurement of either FBG in the pre-DM range (6.1–7.0 mmol/l) or HbA1c in the intermediate range (6.0-6.4%) [12](See Appendix 1). Evaluation of the performance of these laboratory tests for diagnosis of DM in TB patients in a TANDEM cohort has recently been published[9].

Underweight was defined as BMI $< 18 \text{ kg/m}^2$; normal weight BMI of $18 \text{ kg/m}^2 - 24.9 \text{ kg/m}^2$; overweight BMI $25 \text{ kg/m}^2 - 29.9 \text{ kg/m}^2$; and obesity $\geq 30 \text{ kg/m}^2$. In Indonesia accepted BMI categories for South Asian populations were used; overweight was defined as BMI $23 \text{ kg/m}^2 - 27.49 \text{ kg/m}^2$ and obesity as $\geq 27.5 \text{ kg/m}^2$ [13]. Kidney disease was defined according to the National Kidney Foundation guidelines [14]. Principal Component Analysis was performed to build a socio-economic status index classifying study populations from each country in to quintiles based on asset ownership by patients that included non-sellable (possession of a bank account, type of sanitation facility, household water source) and sellable assets (e.g. stove, refrigerator, washing machine, television). [15].

Family history of DM was defined by self-report of having either a parent, sibling or child with DM. Smoking status was recorded from self-report of currently smoking (including those who had quit for less than 6 months), past smokers or having never

smoked. Hypertension was categorised as follows; pre-hypertension systolic or diastolic 120/80-129/80 mmHg, Stage I systolic or diastolic 130/80-139/89 mmHg, Stage II systolic or diastolic over 140/90 mmHg[16]. Ten year risk of a fatal or major cardiovascular event (myocardial infarction or stroke, using WHO/ISH Cardiovascular Risk Prediction Charts)[17] and the Charlson comorbidity index was calculated[18]. To assess TB severity, we used TB score, which is a simple clinical score used for clinical monitoring of TB, and haemoptysis[19].

Data analysis

We used REDCap 6.9.1 [20] for data collection and management and STATA 15.0 (StataCorp, Texas, USA) for statistical analysis. Categorical variables were presented with their frequencies and continuous variables summarized using mean and standard deviation (SD) or where appropriate median and interquartile ranges (IQR). Between country comparisons were done using the non-parametric Kruskal-Wallis and Chi-square tests were performed for categorical variables and for continuous variables, t-test or ANOVA. The crude prevalence of DM was calculated for each country overall and stratified by age group. A directly standardised prevalence rate was also calculated using the World Standard Population as a reference [21]. Factors potentially associated with prevalent DM were assessed by calculating crude odds ratios. All factors significant at $P < 0.15$ in this univariate analysis were then included in a multivariate model. A multi-level mixed effect regression model was used, with country entered as a random error term (representing a random intercept) and robust standard errors calculated using “country” as a cluster variable to account for the clustering of TB-DM patients within

countries. In sensitivity analyses, alternative models were explored where country was entered as a fixed effect and interaction terms included between age groups and country.

Ethics

This study was approved by the Institutional Review Board (IRB) at the London School of Hygiene and Tropical Medicine as the TANDEM Coordinating Centre (Ethics Reference Number 6449), and approved by the local IRB at each site. All participants were provided with an information sheet explaining the study and provided written informed consent.

Results

A total of 2185 pulmonary TB patients were enrolled (Indonesia n=748; Peru n=600; Romania n=506 and South Africa n=331). Most patients were male (61.2%), the median age was 36.6 years (IQR: 26.0-49.1) and 82 patients (3.8%) were HIV positive, the highest proportion from South Africa (9.7%) (Table 1). Of the TB patients recruited, 78.8% had bacteriologically confirmed disease, either positive on culture (78.8%), or sputum smear (72.5%). One quarter of patients (24.6%) reported a previous TB episode. More than half reported having ever smoked, with the highest frequencies in South Africa (86.1%) and Indonesia (62.0%). The overall median BMI was 19.6 kg/m² in males and 20.6 kg/m² in females with 2.2% of patients obese, highest in Peru at 3.7% (Table 1).

Of the 2185 patients, 57 were missing data on DM diagnostic tests. A total of 267 TB patients had confirmed DM after repeated testing; a crude prevalence of 12.5% (95% CI 11.1% to 14.0%). Age standardised DM prevalence was highest in Indonesia at 19.7% (95% CI:16.8%-22.5%), similar in Peru (12.3%; 95%CI:9.2%-15.3%) and Romania (12.3%; 95% CI: 9.7%-15.0%), and lowest in South Africa at 10.9% (95%CI: 7.0%-14.9%). More than two-thirds of diabetes detected in this study had already been previously diagnosed; 12.8% of TB patients in Indonesia, 5.8% in Peru, 6.9% in Romania and 5.1% in South Africa. There were substantial between-country differences in HbA1c values among TB-DM patients with a median HbA1c of 11.3% among TB-DM patients in Indonesia, 10.6% in Peru, 7.4% in Romania and 10.1% in South Africa.

Compared to TB patients without DM, TB-DM patients were more frequently smear (72.7% vs 80.2%, p=0.009) and culture positive (81.4% vs 91.5%, p<0.001, table 3).

TB patients with DM were older (median age 51.0 vs. 33.0 years, $p<0.001$), had higher BMI (21.9 vs 19.6 kg/m², $p<0.001$) and lower waist-hip ratios (Male 0.86 vs 0.89, $p<0.001$; Female 0.83 vs 0.87 <0.001), lower socioeconomic status (wald test $p<0.001$), were more likely to have a family history of DM (aOR 3.7 (1.8 - 7.3), $p<0.001$) and less likely to have been previously treated for TB (16.9% vs 25.7%, $p=0.02$) when compared to those without DM (tables 2 and 3). Haemoptysis was slightly more common in TB-DM patients (30.0% vs 26.6%, $p=0.1$), and TB Score was higher among TB-DM patients in Indonesia. Individuals with TB-DM were also more likely to have more than 10% risk of a major CVD event occurring within 10 years compared to those with TB (24.5% vs 5.5%, table 3). In female patients, anaemia was consistently less frequent among those with DM (42.1% vs 52.1% overall, $p=0.001$), but there was little difference in anaemia prevalence amongst men except in Indonesia (56.1% TB only vs 29.5% TB-DM, $p<0.001$).

TB patients with newly and previously diagnosed DM were of similar age (52.1 vs 51.0; Table 4). However, compared to TB patients with previously known DM, those with a new DM diagnosis had a worse TB score on diagnosis (77.4% had a score of 3 or above, compared with 65.6% of known DM patients, $p<0.001$) suggesting greater TB disease severity, lower BMI (20.0 vs 22.5, $p=0.02$) and lower HbA1c (8.0% vs 10.9%, $p=0.05$). They were also less likely to have a family history of DM (19.1% vs 43.2%, $p<0.001$), had lower Charlson co-morbidity index (CMI) scores (2.4% vs 47.0% had a score ≥ 2 , $p<0.001$) and fewer DM complications including hypertension and macro or microvascular disease (2.4% vs 43.2%, $p<0.001$) (Table 4).

Despite the poor DM control evidenced by high HbA1c results, a significant proportion of those with a previous DM diagnosis reported taking insulin (20.2%) or metformin (61.2%). The overall poor health of this group of patients was clear from the high proportion (20.0%) reporting at least one DM-attributable hospital admission in the preceding 5 years.

TB patients with intermediate hyperglycaemia (or “pre-diabetes”) were slightly older compared to those with TB only (median age of 39 vs 32), but otherwise appeared to be more like TB-only patients than TB-DM patients in terms of BMI and disease characteristics (Supplementary Table 1).

Discussion

In this multi-country cohort patients with newly diagnosed TB had a high prevalence of both newly diagnosed (3.8%) and previously known (8.4%) DM. Diabetes prevalence amongst TB patients varied between countries, as did the proportion of known versus newly diagnosed DM. DM was very uncommon in younger patients, with the risk of having DM increasing substantially for those 35 years and over, and between 20-35% of TB patients aged over 50 years old having new or previously diagnosed DM. Most patients had been diagnosed with DM relatively recently, many within the past year. Amongst these individuals TB may have been their first complication of DM, and amongst those newly diagnosed with DM their incident TB disease revealed their underlying DM.

TB patients with known DM were characterised by poor glycaemic control despite their knowledge of their DM status (median HbA1c 10.9% with outlying values as high as 17%). Better glycaemic control is known to reduce future risk of macro- and

microvascular disease and would likely reduce the risk of many infections among DM patients[22]. Though direct evidence that enhanced glycaemic control reduces TB risk is lacking, the increased risk of TB amongst individuals with DM [6] and the association with poorer TB treatment outcomes[3], suggest that improved glycaemic control should be amongst the suite of interventions to prevent TB especially in areas with high TB prevalence. Cases of TB in poorly controlled DM may be viewed as missed opportunities for TB prevention; conversely, incident TB, when adequately treated, provides a “second chance” to re-engage previously neglected patients back into DM care. Incident TB also offers an opportunity for new diagnosis and management of previously unrecognised DM, potentially reducing downstream DM-related morbidity.

Our findings are consistent with earlier studies that show age is an important risk factor for DM among TB patients [23-25]. Obesity was also strongly associated with diabetes [26], in line with some [27-29] but not all studies [30]. Whilst obesity is well known to be a strong risk factor for diabetes in the general population, it has not always been identified as a risk factor among TB patients, likely due to the weight loss that often accompanies TB disease. Besides obesity and increasing age, family history of DM was also strongly associated with having DM in this population.

At 21%, the prevalence of intermediate hyperglycaemia (“pre-diabetes”) identified in TB patients was higher than expected, although a rising prevalence of intermediate hyperglycaemia has been reported in LMICs [31]. This figure would have even been higher based on point-of-care HbA1c results[10], or use of the lower American Diabetes Association cut-point. Caution is advised in interpreting the significance of intermediate hyperglycemia as transient hyperglycaemia may occur in hypermetabolic inflammatory

conditions and infections, including TB[32] (see Supplementary Figure 1)[9]. The definition of intermediate hyperglycaemia itself is under scrutiny as DM only develops within 10 years in <50% of those identified with pre-DM based on a single FBG or HbA1c test [33], and uncertainty about the cut-point when using HbA1c. Our data suggest that TB patients with intermediate hyperglycaemia were clinically more like those without diabetes than people with diabetes. Over- diagnosis and over-treatment of intermediate hyperglycaemia [34] may increase potentially unnecessary risks (stress, drug adverse events) in vulnerable populations such as those with TB, and does not appear warranted on the basis of our data.

Patients with previously diagnosed DM often had serious comorbidities and DM complications such as chronic kidney disease which itself is an independent risk factor for TB [35], and microvascular and/or macrovascular complications. Patients with newly diagnosed DM had fewer DM complications, but more severe TB, despite better glycaemic control, suggesting that some of those newly diagnosed were experiencing “transient hyperglycaemia” due to severe TB. In general, TB patients with diabetes appeared to have somewhat worse TB disease compared to those without DM.

For patients with TB-DM an important consideration in the aftermath of successful TB treatment is glycemic control and management of cardiovascular risk associated with DM. Despite poor glycemic control, only 20% of TB patients with previously known DM used insulin, and only 61% used metformin. Also, hypertension was common but often untreated. These figures are in line with significant gaps in management of DM in general that we found in these same settings[36].

The between-country heterogeneity for certain parameters (HbA1c and BMI distributions) highlights the inherent variability across different populations and epidemiological settings. Though this observation is a finding that stresses the importance of understanding the local in-country epidemiology, it adds complexity to analyses which pool data from such diverse sites. We used robust standard errors to adjust for clustering within sites, and included country as a random effect in our regression modelling.

A potential limitation of this study is that laboratory tests were taken at the time of diagnosis and confirmatory tests up to 2 weeks later. Elevated measurements may therefore reflect stress hyperglycaemia, overestimating DM prevalence [37] although available repeated HbA1c or FBG tests at the end of TB treatment remained abnormal in the large majority (not shown).

This study has many strengths: all patients were screened for DM with HbA1c, a standardized and validated measure in accredited laboratories, and the recruitment processes were standardized (using case record forms, standard operating procedures, and standardized definitions of all major variables), which enhances the cross-site comparability. In contrast to many studies of DM prevalence among TB patients, a repeated laboratory based measure was used for screening. Many earlier studies have been limited to a single test, often using point of care methods, not universally considered appropriate for DM diagnosis [11]. The case-definition used here is thus likely to be more robust. Recruitment criteria were specific, but sufficiently flexible to ensure the representativeness of participants within sites, and included microbiological assessment of TB status.

Our data enforce recently updated recommendations regarding DM screening and management among TB patients published by the UNION (International Union Against Tuberculosis and Lung Diseases) and World Diabetes Foundation[38]. These aimed to help front-line health workers at TB and DM clinics and highlight some of the challenges in management of comorbid disease[22]. However, stronger evidence (particularly in implementation of comorbidity care & treatment) are urgently needed. Further longitudinal studies exploring the role and importance of transient hyperglycaemia in TB patients and its association with future DM are also essential, as are studies examining the longer-term effects of DM screening and management on both TB and DM outcomes. Future studies should explore improved models of care, such as training of health care professionals to deliver integrated management of TB-DM in primary care in LMIC. Such integrated management could increase uptake of appropriate secondary preventive therapies for patients with TB-DM at high risk of cardiovascular disease, and may also improve TB treatment outcomes[39], given the high prevalence of uncontrolled DM at baseline in our cohort. Attention should also be paid to health systems interventions to enhance and promote referral to local DM services after the end of TB treatment. Despite this evident need, there are no published randomized controlled trials that have explored integrated management options, and a paucity of on-going studies addressing these key clinical issues[39, 40].

Author contributions

HMD, RvC, PCH, BA, RR, JAC, MI, GW, and DM obtained funding for the project and designed the study. All authors contributed to data collection and quality assurance. FP and JAC developed the statistical analysis plan and performed analyses. CUG drafted the manuscript. All authors critiqued the paper for important intellectual content, contributed to manuscript revision and approved the final version.

Acknowledgments

TANDEM Consortium Member List is in the Supplementary Table 2.

FUNDING

This work was supported by the TANDEM project, which was funded by the European Union's Seventh Framework Programme (FP7/2007–2013) under Grant Agreement Number 305279. This publication was made possible by NPRP grant number 7-627-3-167 from the Qatar National Research Fund (a member of Qatar Foundation). The findings achieved herein are solely the responsibility of the authors.

Disclosure

The authors report no conflicts of interest in this work.

References

1. Zimmet PZ, Magliano DJ, Herman WH, Shaw JE. Diabetes: a 21st century challenge. *The lancet Diabetes & endocrinology* **2014**; 2(1): 56-64.
2. International Diabetes Federation. IDF Diabetes Atlas, 8th edn. Vol. <http://www.idf.org/diabetesatlas> (last accessed 17/05/2016). Brussels, Belgium, **2017**.
3. Huangfu P, Ugarte-Gil C, Golub J, Pearson F, Critchley J. The effects of diabetes on tuberculosis treatment outcomes: an updated systematic review and meta-analysis. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease* **2019**: (In Press).
4. WHO. Global tuberculosis report 2018. 20th ed, **2018**.
5. Ronacher K, van Crevel R, Critchley JA, et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 2: Underlying Biologic Mechanisms. *Chest* **2017**; 152(1): 174-80.
6. Jeon CY, Murray MB. Diabetes mellitus increases the risk of active tuberculosis: a systematic review of 13 observational studies. *PLoS medicine* **2008**; 5(7): e152.
7. van Crevel R, Dockrell HM. TANDEM: understanding diabetes and tuberculosis. *The lancet Diabetes & endocrinology* **2014**; 2(4): 270-2.
8. Critchley JA. Appendices to "Diabetes screening in tuberculosis patients: a diagnostic accuracy analysis of risk scores and laboratory methods in Indonesia, Peru, Romania

and South Africa". Available at:

https://figshare.com/articles/Appendices_to_Diabetes_screening_in_tuberculosis_patients_a_diagnostic_accuracy_analysis_of_risk_scores_and_laboratory_methods_in_Indonesia_Peru_Romania_and_South_Africa_/6809675.

9. Grint D, Alisjhabana B, Ugarte-Gil C, et al. Accuracy of diabetes screening methods used for people with tuberculosis, Indonesia, Peru, Romania, South Africa. *Bull World Health Organ* **2018**.
10. Huangfu P, Laurence YV, Alisjhabana B, et al. Point of care HbA1c level for diabetes mellitus management and its accuracy among tuberculosis patients: a study in four countries. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease* **2019**; 23(3): 283-92.
11. WHO. Use of glycated haemoglobin (HbA1c) in diagnosis of diabetes mellitus: abbreviated report of a WHO consultation. **2011**.
12. John WG. Use of HbA1c in the diagnosis of diabetes mellitus in the UK. The implementation of World Health Organization guidance 2011. *Diabetic medicine : a journal of the British Diabetic Association* **2012**; 29(11): 1350-7.
13. WHO. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *The Lancet* **2004**; 363(9403): 157-63.

14. Daugirdas JT, Depner TA, Inrig J, et al. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 Update. *American Journal of Kidney Diseases* **2016**; 66(5): 884-930.
15. Vyas S, Kumaranayake L. Constructing socio-economic status indices: how to use principal components analysis. *Health policy and planning* **2006**; 21(6): 459-68.
16. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. *Journal of the American College of Cardiology* **2018**; 71(19): e127.
17. assessment WHOJPocdgm, WHO mocrG. WHO/ISH cardiovascular risk prediction charts. **2007**.
18. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *Journal of chronic diseases* **1987**; 40(5): 373-83.
19. Wejse C, Gustafson P, Nielsen J, et al. TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. *Scandinavian journal of infectious diseases* **2008**; 40(2): 111-20.
20. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for

- providing translational research informatics support. *Journal of biomedical informatics* **2009**;
42(2): 377-81.
21. World Health Organization. Age Standardization of rates: a new WHO standard. Vol.
EIP/GPE/EBD GPE Discussion Paper Series: No.31
<http://www.who.int/healthinfo/paper31.pdf>, **2001**.
22. van Crevel R, Koesoemadinata R, Hill PC, Harries AD. Clinical management of combined
tuberculosis and diabetes. *The international journal of tuberculosis and lung disease : the
official journal of the International Union against Tuberculosis and Lung Disease* **2018**;
22(12): 1404-10.
23. Wu Z, Guo J, Huang Y, et al. Diabetes mellitus in patients with pulmonary tuberculosis
in an aging population in Shanghai, China: Prevalence, clinical characteristics and
outcomes. *Journal of diabetes and its complications* **2015**.
24. Workneh MH, Bjune GA, Yimer SA. Prevalence and Associated Factors of Diabetes
Mellitus among Tuberculosis Patients in South-Eastern Amhara Region, Ethiopia: A Cross
Sectional Study. *PloS one* **2016**; 11(1): e0147621.
25. Restrepo BI, Camerlin AJ, Rahbar MH, et al. Cross-sectional assessment reveals high
diabetes prevalence among newly-diagnosed tuberculosis cases. *Bull World Health Organ*
2011; 89(5): 352-9.

26. Abdullah A, Peeters A, de Courten M, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: A meta-analysis of prospective cohort studies. *Diabetes Research and Clinical Practice* **2010**; 89(3): 309-19.
27. Magee MJ, Kempker RR, Kipiani M, et al. Diabetes mellitus is associated with cavities, smear grade, and multidrug-resistant tuberculosis in Georgia. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease* **2015**; 19(6): 685-92.
28. Viswanathan V, Kumpatla S, Aravindalochanan V, et al. Prevalence of diabetes and pre-diabetes and associated risk factors among tuberculosis patients in India. *PloS one* **2012**; 7(7): e41367.
29. Perez-Navarro LM, Fuentes-Dominguez F, Morales-Romero J, Zenteno-Cuevas R. Factors associated to pulmonary tuberculosis in patients with diabetes mellitus from Veracruz, Mexico. *Gaceta medica de Mexico* **2011**; 147(3): 219-25.
30. Faurholt-Jepsen D, Range N, PrayGod G, et al. The role of anthropometric and other predictors for diabetes among urban Tanzanians with tuberculosis. *The International Journal of Tuberculosis and Lung Disease* **2012**; 16(12): 1680-5.
31. Shen J, Kondal D, Rubinstein A, et al. A Multiethnic Study of Pre-Diabetes and Diabetes in LMIC. *Glob Heart* **2016**; 11(1): 61-70.

32. Boillat-Blanco N, Ramaiya KL, Mganga M, et al. Transient Hyperglycemia in Patients With Tuberculosis in Tanzania: Implications for Diabetes Screening Algorithms. *The Journal of infectious diseases* **2015**.
33. Morris DH, Khunti K, Achana F, et al. Progression rates from HbA1c 6.0-6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. *Diabetologia* **2013**; 56(7): 1489-93.
34. Yudkin JS, Montori VM. Comment on Cefalu et Al. The alarming and rising costs of diabetes and prediabetes: a call for action! *Diabetes care* 2014;37:3137-3138. *Diabetes care* **2015**; 38(5): e81.
35. Moran E, Baharani J, Dedicoat M, et al. Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease. *The Journal of infection* **2018**; 77(4): 291-5.
36. Soetedjo NNM, McAllister SM, Ugarte-Gil C, et al. Disease characteristics and treatment of patients with diabetes mellitus attending government health services in Indonesia, Peru, Romania and South Africa. *Tropical medicine & international health : TM & IH* **2018**; 23(10): 1118-28.
37. Kornfeld H, West K, Kane K, et al. High Prevalence and Heterogeneity of Diabetes in Patients With TB in South India: A Report from the Effects of Diabetes on Tuberculosis Severity (EDOTS) Study. *Chest* **2016**; 149(6): 1501-8.

38. Lin Y, Harries AD, Kumar AVM, et al. Management of Diabetes Mellitus-Tuberculosis: a guide to the essential practice, 2018.
39. Shewade HD, Jeyashree K, Mahajan P, et al. Effect of glycemc control and type of diabetes treatment on unsuccessful TB treatment outcomes among people with TB-Diabetes: A systematic review. PloS one 2017; 12(10): e0186697.
40. Critchley JA, Restrepo BI, Ronacher K, et al. Defining a Research Agenda to Address the Converging Epidemics of Tuberculosis and Diabetes: Part 1: Epidemiology and Clinical Management. Chest 2017; 152(1): 165-73.

Table 1. Baseline characteristics

| <i>Characteristics</i> | | <i>Total (N=2185)</i> | <i>Indonesia (N=748)</i> | <i>Peru (N=600)</i> | <i>Romania (N=506)</i> | <i>South Africa (N=331)</i> |
|---------------------------------------|----------|---------------------------|------------------------------|-------------------------|----------------------------|---------------------------------|
| Median Age (IQR) | | 36.6 (25.5-49.1) | 37.0 (27.0-49.0) | 30.0 (22.0 - 43.0) | 43.0 (30.0 – 54.0) | 35.0 (28.0 - 48.0) |
| ≥35 years old (%) | | 1171 (53.6%) | 416 (55.6%) | 246 (41.0%) | 341 (67.4%) | 168 (50.8%) |
| Gender (%) | Male | 1337 (61.2%) | 426 (57.0%) | 348 (58.0%) | 358 (70.8%) | 205 (61.9%) |
| Median BMI kg/m ² (IQR) | All | 19.9 (17.7-22.5) | 18.2 (16.3-20.6) | 22.1 (20.0-24.4) | 20.3 (18.7-22.2) | 18.5 (17.0-20.8) |
| | Male | 19.6 (17.5-21.9) | 17.8 (16.1-19.7) | 21.7 (19.9-23.8) | 20.3 (18.8-22.0) | 18.2 (16.6-20.0) |
| | Female | 20.6 (18.0-23.4) | 19.2 (16.7-22.1) | 22.7 (20.0-25.3) | 20.3 (18.3-22.6) | 19.5 (17.7-22.6) |
| Obesity (BMI≥30) ¹ | | 49 (2.2%) | 14 (1.9%) | 22 (3.7%) | 4 (0.8%) | 9 (2.7%) |
| HIV status ² (%) | Positive | 82 (3.8%) | 26 (3.5%) | 23 (3.8%) | 1 (0.2%) | 32 (9.7%) |
| Sputum smear result (%) | Positive | 1583 (72.5%) | 629 (84.1%) | 387 (64.5%) | 345 (68.2%) | 222 (67.1%) |
| | Missing | 34 (1.6%) | 1 (0.1%) | 2 (0.3%) | 13 (2.6%) | 18 (5.4%) |
| Sputum culture result (%) | Positive | 1721 (78.8%) | 610 (81.6%) | 491 (81.8%) | 390 (77.1%) | 230 (69.5%) |
| | Missing | 113 (5.2%) | 25 (3.3%) | 2 (0.3%) | 25 (4.9%) | 11(30.1%) |
| Previous TB (%) | Yes | 538 (24.6%) | 185 (24.7%) | 123 (20.5%) | 97 (19.2%) | 133 (40.2%) |
| Fever, ≥38°C (%) | Yes | 123 (5.6%) | 38 (5.1%) | 34 (5.7%) | 32 (6.3%) | 19 (5.7%) |

| Characteristics | | Total (N=2185) | Indonesia (N=748) | Peru (N=600) | Romania (N=506) | South Africa (N=331) |
|------------------------|-----------------|---------------------------|------------------------------|-------------------------|----------------------------|---------------------------------|
| Smoking (%) | Current | 903 (41.3%) | 132 (17.7%) | 66 (11%) | 233 (46.1%) | 273 (82.5%) |
| | Past | 355 (16.3%) | 331 (44.3%) | 178 (29.7%) | 33 (6.5%) | 12 (3.6%) |
| | Never | 927 (42.4%) | 285 (38.1%) | 356 (59.3%) | 240 (47.4%) | 46 (13.9%) |
| Weight loss (%) | (>=10kg) | 163 (7.5%) | 67 (9.0%) | 30 (5.0%) | 20 (4.0%) | 46 (13.9%) |
| | (5-10kg) | 610 (27.9%) | 259 (34.6%) | 135 (22.5%) | 119 (23.5%) | 97 (29.3%) |
| | (< 5kg) | 917 (42.0%) | 292 (39.0%) | 248 (41.3%) | 216 (42.7%) | 161 (48.6%) |
| Haemoptysis | Any | 532 (24.4%) | 228 (30.5%) | 195 (32.5%) | 48 (9.5%) | 61 (18.4%) |
| TB Score | 0 to 2 | 691 (31.6%) | 109 (14.6%) | 274 (45.7%) | 251 (49.6%) | 57 (17.2%) |
| | 3 to 5 | 1184 (54.2%) | 408 (54.6%) | 311 (51.2%) | 235 (46.4%) | 230 (69.5%) |
| | 6+ | 310 (14.2%) | 231 (30.9%) | 15 (2.5%) | 20 (4.0%) | 44 (13.3%) |
| Diabetes (%) | No | 1348 (61.7%) | 523 (69.2%) | 464 (77.3%) | 209 (41.3%) | 152 (45.9%) |
| | Pre-DM | 458 (21.0%) | 90 (12.0%) | 82 (13.7%) | 199 (39.3%) | 87 (26.3%) |
| | New DM | 84 (3.8%) | 32 (4.3%) | 12 (2.0%) | 31 (6.2%) | 3 (0.9%) |
| | Known | 183 (8.4%) | 96 (12.8%) | 35 (5.8%) | 35 (6.9%) | 17 (5.1%) |
| | DM ³ | | | | | |
| | Missing data | 57 (2.6%) | 3 (0.4%) | 1 (0.2%) | 0 (0%) | 53 (16.0%) |

| Characteristics | | Total (N=2185) | Indonesia (N=748) | Peru (N=600) | Romania (N=506) | South Africa (N=331) |
|--------------------------|----------------|---------------------------|------------------------------|-------------------------|----------------------------|---------------------------------|
| Education | ≤ Primary | 593 (27.2%) | 240 (32.1%) | 99 (16.5%) | 48 (9.6%) | 206 (62.2%) |
| | ≥ Secondary | 1582 (72.5%) | 508 (67.9%) | 500 (83.3%) | 452 (89.7%) | 122 (36.9%) |
| Socio-Economic Status | Quintile 1 | 627 (28.7%) | 202 (27.0%) | 161 (26.8%) | 176 (34.8%) | 88 (26.6%) |
| | Quintile 2 | 501 (22.9%) | 178 (23.8%) | 125 (20.8%) | 122 (24.1%) | 76 (23.0%) |
| | Quintile 3 | 451 (20.6%) | 181 (24.2%) | 106 (17.7%) | 100 (19.8%) | 64 (19.3%) |
| | Quintile 4 | 358 (16.4%) | 129 (17.3%) | 108 (18.0%) | 67 (13.2%) | 54 (16.3%) |
| | Quintile 5 | 207 (9.5%) | 53 (7.1%) | 90 (15.0%) | 26 (5.1%) | 38 (11.5%) |
| | Missing | 41 (1.9%) | 5 (0.7%) | 10 (1.7%) | 15 (3.0%) | 11 (3.3%) |

Figures rounded to 1DP including percentages, percentage given of relevant whole sample with missing values only noted where >3%. Some figures may differ from other TANDEM analyses due to minor differences in inclusion criteria or case definitions.

IQR=interquartile range

¹ obesity in Indonesian population defined as BMI>27.5 kg/m²

² HIV status data was only available for 730 patients in Indonesia, 506 in Peru, 364 in Romania and 328 in South Africa.

³ both self-report of prior DM diagnosis and either (a) use of DM medication or (b) study HbA1c of ≥6.5%

Table 2 - Factors associated with DM (new or previously diagnosed) among TB patients over 35 years of age

| <i>Factors</i> | | <i>Crude OR (95% CI)</i> | <i>P-value</i> | <i>Adjusted OR (95% CI)</i> | <i>P-value</i> |
|-----------------------|-------------|--------------------------|----------------|-----------------------------|----------------|
| Age | 35-44 years | 1 | | 1 | |
| | 45-54 years | 3.2 (1.4 - 6.6) | 0.006 | 2.9 (1.5 - 5.9) | 0.004 |
| | 55-64 years | 3.8 (2.8 - 5.3) | <.0001 | 3.6 (2.8 - 4.5) | <0.001 |
| | >65 years | 3.5 (2.6 - 4.7) | <.0001 | 3.5 (2.3 - 5.3) | <0.001 |
| Gender | Female | 1 | | 1 | |
| | Male | 0.7 (0.5 - 0.9) | 0.003 | 0.9 (0.7 - 1.0) | 0.1 |
| Smear test result | Negative | 1 | | 1 | |
| | Positive | 0.8 (0.4-1.4) | 0.4 | 0.9 (0.4-1.7) | 0.7 |
| | Missing | 1.4 (0.9-2.2) | 0.09 | 1.9 (1.2-3.0) | 0.007 |
| Previous TB episode | No | 1 | | 1 | |
| | Yes | 0.4 (0.3 - 0.6) | <.0001 | 0.5 (0.3 - 0.9) | 0.02 |
| BMI | Underweight | 0.5 (0.4 - 0.7) | <0.001 | 0.4 (0.3 - 0.5) | <0.001 |
| | Normal | 1 | | 1 | |
| | Overweight | 2.3 (1.4 - 3.8) | 0.001 | 2.0 (1.3 - 3.3) | 0.003 |
| | Obese | 5.9 (1.98 - 17.0) | 0.002 | 6.5 (1.7 - 24.7) | 0.006 |
| Family history of DM | No | 1 | | 1 | |
| | Yes | 3.6 (2.0 - 6.6) | <.0001 | 3.7 (1.8 - 7.3) | <0.001 |
| Socio Economic Status | 1 (richest) | 1 | | 1 | |
| | 2 | 1.1 (0.8-1.3) | 0.5 | 1.0 (0.7 - 1.4) | 0.9 |

| <i>Factors</i> | | <i>Crude OR (95% CI)</i> | <i>P-value</i> | <i>Adjusted OR (95% CI)</i> | <i>P-value</i> |
|----------------------------------|--------------|--------------------------|--------------------|-----------------------------|------------------|
| | 3 | 1.6 (1.3 - 2.1) | <0.001 | 1.2 (1.1- 1.3) | <0.001 |
| | 4 | 1.3 (0.8 – 2.1) | 0.4 | 0.8 (0.6- 1.0) | 0.08 |
| | 5 (poorest) | 1.9 (1.0 – 3.7) | 0.005 ¹ | 1.43 (0.6 – 2.7) | 0.5 ¹ |
| Country (Indonesia as reference) | Indonesia | 1 | | ² | |
| | Peru | 0.5 (0.3-0.8) | 0.002 | | |
| | Romania | 0.5 (0.4-0.8) | <0.001 | | |
| | South Africa | 0.4 (0.3-0.5) | <0.001 | | |

¹ Wald test for statistical significance across categories of SES, p<0.001

² Country entered as a random effect into the adjusted model

Table 3. Comparison of TB patients with and without diabetes (TB-DM and TB respectively)

| | <i>Total</i> | | | <i>Indonesia</i> | | | <i>Peru</i> | | | <i>Romania</i> | | | <i>South Africa</i> | | | |
|--|-------------------------------------|----------------------------------|-----------------|------------------------------------|----------------------------------|-----------------|------------------------------------|---------------------------------|-----------------|------------------------------------|---------------------------------|------------------|------------------------------------|---------------------------------|-----------------|-------|
| | <i>TB-only</i> (<i>N=1918</i>) | <i>TB-DM</i> (<i>N=267</i>) | <i>P</i> | <i>TB-only</i> (<i>N=620</i>) | <i>TB-DM</i> (<i>N=128</i>) | <i>P</i> | <i>TB-only</i> (<i>N=553</i>) | <i>TB-DM</i> (<i>N=47</i>) | <i>P</i> | <i>TB-only</i> (<i>N=440</i>) | <i>TB-DM</i> (<i>N=66</i>) | <i>P</i> | <i>TB-only</i> (<i>N=305</i>) | <i>TB-DM</i> (<i>N=26</i>) | <i>P</i> | |
| Median age (IQR) | 33.0 (27.0-47.0) | 51.0 (45.0-59.0) | <0.001 | 34.10 (25.3-45.0) | 50.5 (45.1-57.8) | <0.001 | 28.0 (22.0-39.5) | 51.0 (47.0-58.0) | <0.001 | 41.0 (27.0-52.0) | 56.0 (45.0-65.0) | <0.001 | 32.0 (27.0-47.0) | 45.5 (40.5-52.0) | <0.001 | |
| ≥35 years old (%) | 48.1% | 93.0% | <0.001 | 47.7% | 93.8% | <0.001 | 36.7% | 91.5% | <0.001 | 63.2% | 95.4% | <0.001 | 47.8% | 84.6% | <0.001 | |
| Gender (% male) | 62.0% | 55.4% | <0.001 | 58.9% | 47.7% | 0.02 | 58.6% | 51.1% | 0.3 | 69.8% | 77.3% | 0.2 | 63.3% | 46.2% | 0.08 | |
| Previous TB (%) | 25.7% | 16.9% | 0.02 | 25.7% | 20.3% | 0.3 | 21.0% | 14.9% | 0.3 | 20.2% | 12.1% | 0.09 | 42.3% | 15.4% | 0.007 | |
| Smoking* (%) | Current smoker | 42.7% | 31.8% | 46.5% | 33.6% | 11.9% | 0% | 47.5% | 36.4% | 83.6% | 69.2% | 0.001 | 3% | 11.5% | 0.001 | |
| | Past smoker | 16.2% | 16.5% | 17.3% | 19.5% | 30.2% | 23.4% | 6.4% | 7.6% | 3% | 11.5% | 0.001 | 3% | 11.5% | 0.001 | |
| | Never smoker | 41.1% | 51.7% | 36.3% | 46.9% | 57.9% | 76.6% | 46.1% | 56.1% | 13.4% | 19.2% | 0.001 | 13.4% | 19.2% | 0.001 | |
| Median BMI (kg/m²) | 19.6 (17.6-22.1) | 21.9 (19.0-25.7) | <0.001 | 17.9 (16.1-19.9) | 21.1 (18.4-24.9) | <0.001 | 21.9 (19.9-24.1) | 24.7 (21.8-28.4) | <0.001 | 20.2 (18.5-22.0) | 21.4 (19.3-23.9) | 0.02 | 18.4 (16.9-20.3) | 22.3 (18.6-27.0) | 0.004 | |
| Mean WHR | Men (SD) | 0.86 (0.067) | 0.89 (0.077) | <0.001 | 0.83 (0.068) | 0.88 (0.063) | <0.0001 | 0.89 (0.060) | 0.95 (0.067) | <0.0001 | 0.86 (0.063) | 0.88 (0.088) | 0.07 | 0.86 (0.059) | 0.89 (0.072) | 0.063 |
| | Women (SD) | 0.83 (0.073) | 0.87 (0.077) | <0.001 | 0.81 (0.071) | 0.86 (0.072) | <0.0001 | 0.87 (0.062) | 0.91 (0.078) | 0.007 | 0.79 (0.072) | 0.829 (0.090) | 0.06 | 0.83 (0.58) | 0.89 (0.056) | 0.001 |
| Mean Laboratory HbA1c(%) | 5.6 (5.3-5.9) | 10.4 (7.9-12.3) | <0.001 | 5.5 (5.3-5.8) | 11.3 (9.1-12.9) | <0.001 | 5.5 (5.2-5.8) | 10.6 (9.0-13.3) | <0.001 | 5.8 (5.5-6.1) | 7.4 (6.7-10.8) ¹ | <0.001 | 5.8 (5.5-6.1) | 10.1 (7.8-11.9) | <0.001 | |
| Antihypertensive medication use (%) | 3.2% | 16.9% | <0.001 | 4.0% | 13.3% | <0.001 | 0.5% | 8.5% | <0.001 | 4.1% | 22.7% | <0.001 | 5.0% | 34.6% | <0.001 | |

| | Total | | | Indonesia | | | Peru | | | Romania | | | South Africa | | | |
|--|----------------------------|-------------------------|----------|---------------------------|-------------------------|----------|---------------------------|------------------------|----------|---------------------------|------------------------|----------|---------------------------|------------------------|----------|-------|
| | <i>TB-only</i> (N=1918) | <i>TB-DM</i> (N=267) | <i>P</i> | <i>TB-only</i> (N=620) | <i>TB-DM</i> (N=128) | <i>P</i> | <i>TB-only</i> (N=553) | <i>TB-DM</i> (N=47) | <i>P</i> | <i>TB-only</i> (N=440) | <i>TB-DM</i> (N=66) | <i>P</i> | <i>TB-only</i> (N=305) | <i>TB-DM</i> (N=26) | <i>P</i> | |
| CVD Risk (% with 10 year risk estimated over 10%) | 5.5% | 24.5% | 0.06 | 7.0% | 17.9% | 0.1 | 2.8% | 22.2% | 0.02 | 5.24% | 38% | <0.001 | 5.5% | 8.3% | 0.2 | |
| Smear positive (%) | 72.7% | 80.2% | 0.009 | 83.1% | 89.1% | 0.09 | 64.2% | 68.1% | 0.6 | 67.5% | 72.7% | 0.4 | 67.2% | 65.4% | 1.0 | |
| Culture positive (%) | 81.4% | 91.5% | <0.001 | 79.5% | 91.4% | 0.002 | 82.1% | 89.4% | 0.2 | 76.1% | 83.3% | 0.1 | 83.7% | 88.0% | 1.0 | |
| Smear grade (max at baseline, %) | | | | | | | | | | | | | | | | |
| Negative | 26.8% | 19.5% | 0.0001 | 16.8% | 10.9% | 0.2 | 35.4% | 32.0% | 0.8 | 29.8% | 24.2% | 0.8 | 26.9% | 26.9% | 0.8 | |
| Scanty and 1+ | 31.3% | 30.3% | | 29.4% | 26.6% | | 31.7% | 29.8% | | 33.0% | 34.9% | | 32.1% | 38.5% | | |
| 2+ and 3+ | 40.3% | 48.7% | | 53.7% | 62.5% | | 32.6% | 38.3% | | 34.6% | 37.9% | | 35.1% | 26.9% | | |
| Anaemia amongst men (%)² | 46.9% | 43.2% | 0.8 | 56.1% | 29.5 | <0.001 | 30.3% | 37.5% | 0.5 | 42.4% | 53.0% | 0.2 | 66.8% | 83.3% | 0.2 | |
| Anaemia amongst women (%)² | 52.1% | 42.0% | 0.001 | 61.9% | 49.2 | 0.06 | 38.4% | 26.1% | 0.2 | 48.1% | 40.0% | 0.6 | 62.5% | 35.7% | 0.05 | |
| Haemoptysis (%) | 23.6% | 30.0% | 0.1 | 28.9% | 38.3 | 0.03 | 32.2% | 36.2% | 0.8 | 8.9% | 13.6% | 0.02 | 18.4% | 19.2% | 0.6 | |
| TB Score | 0 to 2 | 31.8% | 0.03 | 13.8% | 18.0% | P<0.001 | 45.3% | 48.9% | 0.5 | 50.7% | 42.4% | 0.3 | 16.1% | 30.8% | 0.09 | |
| | 3 to 5 | 53.4% | | 60.0% | 52.1% | | 66.4% | 51.9% | | 51.1% | 45.7% | | 51.5% | 69.8% | | 65.4% |
| | 6+ | 14.9% | | 9.4% | 34.0% | | 15.6% | 2.7% | | 0.0% | 3.6% | | 6.1% | 14.1% | | 3.8% |

Figures rounded to 1 decimal place including percentages, percentage given of relevant whole sample with missing values only shown where >3%

¹ In Romania, where TB patients are treated as in-patients, repeated FBG measurements were available. 9 of 66 DM patients were classified using FBG rather than repeated HbA1c

² Anaemia defined as Hb<13 in men (n=1337) and <12 in women (n=846)

Table 4 – Comparative characteristics of TB patients with newly and previously diagnosed DM

| | | <i>New DM</i> <i>(N=84)</i> | <i>Known DM</i> <i>(N=183)</i> | <i>P-values</i> |
|------------------------------------|------------|--|---|------------------------|
| Median Age in years (IQR) | | 52.0 (45.1-62.0) | 51.0 (45.1-59.0) | 0.9 |
| Gender (%) | Male | 52 (61.9%) | 96 (52.5%) | 0.2 |
| Haemoptysis | | 28 (35.4%) | 52 (32.1%) | 0.2 |
| TB Score | 0 to 2 | 19 (22.3%) | 63 (34.4%) | <0.001 |
| | 3 to 5 | 51 (60.7%) | 109 (59.6%) | |
| | 6+ | 14 (16.7%) | 11 (6.0%) | |
| Median BMI kg/m ² (IQR) | | 20.0 (17.9-24.5) | 22.5 (19.7-25.9) | 0.02 |
| Median HbA1c% (IQR) | Lab | 8.0 (6.8-11.7) | 10.9 (9.1-12.6) | 0.05 |
| | Repeat | 6.9 (6.5-12.4) | 10.8 (8.9-12.4) | 0.2 |
| Duration of DM diagnosis N (%) | < 1 year | NA | 53 (29.0%) | |
| | 1-5 years | NA | 77 (42.1%) | |
| | 6-15 years | NA | 42 (23.0%) | |
| | 15+ years | NA | 11 (6.0%) | |
| Treatment including Insulin N | | NA | 37 (20.2%) | |

| | | New DM (N=84) | Known DM (N=183) | P-values |
|--|------------------|--------------------------|-----------------------------|---------------------|
| (%) | | | | |
| Treatment including Metformin | | NA | 112 (61.2%) | |
| N (%) | | | | |
| Any hospital admission in the last 5 years due to DM | | NA | 36 (20.0%) | |
| N (%) | | | | |
| Family history of DM | | 16 (19.1%) | 79 (43.2%) | <0.001 |
| N (%) | | | | |
| CMI score ≥ 2 | | 2 (2.4%) | 86 (47.0%) | <0.001 |
| (%) | | | | |
| Any Diabetes Complication | | 2 (2.4%) | 79 (43.2%) | <0.001 |
| (%) | | | | |
| Hypertension | Pre-hypertension | 13 (15.5%) | 15 (8.2%) | <0.001 ¹ |
| | (%) | | | |
| | Stage I | 21 (25%) | 48 (26.2%) | |
| | N (%) | | | |
| | Stage II | 18 (21.4%) | 59 (32.2%) | |
| | N (%) | | | |
| Antihypertensive medication | | 7 (8.3%) | 38 (20.8%) | 0.006 |
| N (%) | | | | |
| Renal function | CKD Stage 3-5 | 2 (2.4%) | 10 (5.5%) | 0.3 |
| N (%) | (eGFR < 60) | | | |

Figures rounded to 1DP including percentages, percentage given of relevant whole sample with missing values only shown where >3%

IQR=interquartile range,

CMI=Charlson co-morbidity index.

NA: Not Applicable

¹ Wald test for statistical significance across categories of hypertension, $p < 0.001$